502 results on '"Siebenhaar, Frank"'
Search Results
2. Mastozytose – eine häufig unerkannte Erkrankung
3. Mastozytose – eine häufig unerkannte Erkrankung
4. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus
5. Non–Skin Related Symptoms Are Common in Chronic Spontaneous Urticaria and Linked to Active and Uncontrolled Disease: Results From the Chronic Urticaria Registry
6. Detecting Changes in Mast Cell Numbers Versus Activation in Human Disease: A Roadblock for Current Biomarkers?
7. Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF©) and determination of a threshold score for moderate symptoms
8. Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
9. Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know
10. The diagnostic workup for systemic mastocytosis differs from consensus recommendations: Results of a worldwide survey
11. Measuring Symptom Severity and Quality of Life in Mastocytosis
12. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
13. Positive Basophil Tests Are Linked to High Disease Activity and Other Features of Autoimmune Chronic Spontaneous Urticaria: A Systematic Review
14. Most Patients With Autoimmune Chronic Spontaneous Urticaria Also Have Autoallergic Urticaria, but Not ViceVersa
15. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
16. Mastocytoses
17. Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond
18. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
19. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
20. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
21. Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases
22. Disease modification in chronic spontaneous urticaria.
23. Stress Affects Mast Cell Proteases in Murine Skin in a Model of Atopic Dermatitis-like Allergic Inflammation
24. Mastocytosis—a frequently unrecognized disease
25. Non-Skin-Related Symptoms are Common in Chronic Spontaneous Urticaria and Linked to Active and Uncontrolled Disease: Results from CURE
26. A systematic review of the clinical evidence for an association between type I hypersensitivity and inner ear disorders
27. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review
28. The Diagnostic Workup in Chronic Spontaneous Urticaria—What to Test and Why
29. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
30. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
31. Validation of the Angioedema Control Test (AECT)—A Patient-Reported Outcome Instrument for Assessing Angioedema Control
32. Physician and Patient Perspectives on Relevant and Burdensome Symptoms of Non-Advanced Systemic Mastocytosis
33. Patient-Reported Outcome Measures in Systemic Mastocytosis: A Systematic Review
34. Prevalence Of The KIT D816V Mutation In Peripheral Blood (PB) Of Patients With Evidence Of Systemic Mast Cell Activation (MCA): Results Of The Prospective, Multi-centered, Global PROSPECTOR Clinical Trial
35. Avapritinib Decreased Symptom Burden in Patients With Indolent Systemic Mastocytosis in the Registrational Double-Blind, Placebo-Controlled PIONEER Study
36. Exploring the Spectrum of Indolent Systemic Mastocytosis: Analysis of High-Risk Disease Features in the PIONEER Study
37. Initial Results from Summit: An On-going, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
38. Correction: Predatory journals: Perception, impact and use of Beall’s list by the scientific community–A bibliometric big data study
39. Mastocytosis—a frequently unrecognized disease
40. Obituary: Professor Marcus Maurer, Berlin, Germany.
41. Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study
42. Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF©
43. Mastozytose
44. Mast cells drive IgE-mediated disease but might be bystanders in many other inflammatory and neoplastic conditions
45. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
46. Response to “Clinical applicability of the Urticaria control test in patients with chronic urticaria: Further evidence from 622 adult and pediatric patients with different disease subtypes”
47. MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial
48. POSTER: MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial
49. Generation and Culture of Peripheral CD34+ Stem Cell-Derived Mast Cells (PSCMCs)
50. Mast Cell-Mediated Reactions In Vivo
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.